FVIII-containing platelets

**FVIII-containing platelets** refer to platelets genetically engineered to express **Factor VIII (FVIII)**, a critical clotting protein deficient in **hemophilia A (HA)**, using platelet-specific promoters like αIIb. This approach delivers FVIII directly to the site of vascular injury via platelet aggregation, bypassing circulating inhibitors and providing effective hemostasis even in patients with anti-FVIII antibodies. Developed as a **gene therapy** strategy, it has demonstrated superior efficacy over plasma-derived FVIII in preclinical models, including resistance to antiplatelet drugs like clopidogrel, and is currently in **Phase I clinical trials**.[1][2]

Other names

platelet-derived FVIIIplatelet-FVIIIplatelet-targeted FVIII